Every 10-Q that AVAI BIO INC (AVAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AVAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVAI filings page.
Avai Bio, Inc. (AVAI) reported for the quarter ended June 30, 2026 with no revenue and a net loss of $552,041, compared with a $487,589 loss a year earlier. Operating expenses were $419,783, and additional other expenses of $132,258 were driven by interest on debt, a discount on a convertible note, and a loss on disposal of a subsidiary.
Total assets were $791,750, versus liabilities of $4,014,316, resulting in a stockholders’ deficit of $3,222,566 and a working capital deficit of $3,860,035. Cash increased to $83,586, supported by $533,299 of net cash from financing activities, including new loans and notes. The company discloses substantial doubt about its ability to continue as a going concern and states its disclosure controls and procedures were not effective. Avai Bio continues to position itself as an AI-focused technology and biotech joint-venture company, adding a Wellness Assessment API and maintaining multiple JV and license agreements while relying on external financing and related-party loans to fund operations.
Avaí Bio, Inc. reported another loss-making quarter with no revenue and a larger deficit. For the three months ended December 31, 2025, the company recorded a net loss of $553,727, bringing the nine‑month loss to $1,494,332.
As of December 31, 2025, Avaí Bio had total assets of $172,912, versus total liabilities of $2,967,398, resulting in a stockholders’ deficit of $2,794,486. Cash and cash equivalents were just $50,402, while accounts payable and various loans and convertible notes made up a heavy current liability load.
The company’s auditors highlight substantial doubt about its ability to continue as a going concern, citing recurring losses and the absence of a stable revenue base. Management plans to rely on additional investment capital while pursuing AI and biotech joint ventures that may require up to tens of millions of dollars in future funding commitments.
Avaí Bio, Inc. (formerly Avant Technologies Inc.) filed its quarterly report for the period ended September 30, 2025. The company reported $0 revenue and a net loss of $453,016 for the quarter. For the six months, net loss was $940,605 as operating expenses focused on G&A, marketing, and initial R&D.
Liquidity remains tight: cash was $91,995 and total assets were $231,372, against total liabilities of $2,532,131, resulting in a stockholders’ deficit of $2,300,759. Management disclosed substantial doubt about the company’s ability to continue as a going concern. Operating cash use for the six months was $611,890, largely offset by $622,832 from financing activities, including related party loans and promissory notes carrying default interest terms.
The company outlined two joint ventures: with Ainnova Tech Inc. (commitment up to $20,000,000 over 12 months) and with Austrianova (up to $1.5 million over 18 months), each at 50/50 ownership. It terminated a prior equity line and withdrew a related S-1, and is pursuing revised financing structures. Common shares outstanding were 137,829,465 at quarter-end and 138,031,533 as of November 14, 2025.